Vertex Pharmaceuticals (VRTX) Q2 2024 Earnings
Vertex Pharmaceuticals reported Q2 2024 revenue of $2.6B, missed analyst consensus of $2.7B by $29.0M. Diluted EPS came in at $-12.83, missed the $-11.63 consensus by $1.20. Vertex Pharmaceuticals reports across 3 business segments, led by Cystic Fibrosis (CF), Hematology and Pain Management, and Specialty Pipeline Programs.
Financial Snapshot
Trailing eight quarters through Q2 2024
Q2 2024 Earnings FAQ
Common questions about Vertex Pharmaceuticals's Q2 2024 earnings report.
Vertex Pharmaceuticals (VRTX) reported Q2 2024 earnings on August 1, 2024 after market close.
Vertex Pharmaceuticals reported revenue of $2.6B and diluted EPS of $-12.83 for Q2 2024.
Revenue missed the consensus estimate of $2.7B by $29.0M. EPS missed the consensus estimate of $-11.63 by $1.20.
You can read the 10-Q periodic report (0000875320-24-000198) directly on SEC EDGAR. The filing index links above go to sec.gov.